ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Open-Label Extension of EryDex Study IEDAT-04-2022

ClinicalTrials.gov ID: NCT06664853

Public ClinicalTrials.gov record NCT06664853. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Extension Study of EryDex in Patients With Ataxia Telangiectasia Following Participation in Study IEDAT-04-2022 (NEAT)

Study identification

NCT ID
NCT06664853
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Enrollment
101 participants

Conditions and interventions

Interventions

  • Dexamethasone sodium phosphate Drug

Drug

Eligibility (public fields only)

Age range
6 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 10, 2024
Primary completion
Jan 29, 2026
Completion
Jan 29, 2026
Last update posted
May 4, 2026

2024 – 2026

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence Los Angeles California 90095
The Johns Hopkins Hospital, Division of pediatric allergy and immunology Baltimore Maryland 21289
Saint Peter's University Hospital, Inc. New Brunswick New Jersey 08901
Cincinnati Children's Hospital, Division of neurology Cincinnati Ohio 45229
UT Health Houston, Department of pediatrics, division of child & adolescent neurology Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06664853, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06664853 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →